Personalisation of antiplatelet therapy and secondary prevention of ischemic stroke.-Reference-Cited by-同舟云学术

Personalisation of antiplatelet therapy and secondary prevention of ischemic stroke.

Published:2018-12-20 Issue:8 Volume:96 Page:677-687
ISSN:2412-1339
Container-title:Clinical Medicine (Russian Journal)
language:
Short-container-title:Klin. med.

Author:

Kitaeva E. Yu.¹^ORCID,Shprakh V. V.¹^ORCID,Mirzaev K. B.²^ORCID,Sychev D. A.²^ORCID

Affiliation:

1. Irkutsk state medical Academy of postgraduate education-branch of THE Russian medical Academy of continuing professional education of the Ministry of health of the Russian Federation

2. Russian medical Academy of continuing professional education of the Ministry of health of the Russian Federation

Abstract

The purpose of this systematic literature review is to highlight the current approach to the issue of “resistance” to antiplatelet drugs, presentation of a personalized approach to antiplatelet therapy in the treatment and secondary prevention of ischemic stroke, taking into account new foreign and Russian recommendations and research results. To achieve this goal, a systematic search was carried out with subsequent analysis of literary data and online resources. All reviews were indexed in PubMed, Medline, elibrary, CyberLeninka, Google Scholar databases. The article presents the main characteristics of the methods of laboratory evaluation of residual platelet reactivity used in clinical practice. It is shown that one of the rational approaches to improving the effectiveness and safety of antiplatelet therapy is to test the sensitivity ofpatients to the antiplatelet action of drugs (aggregatometry). In turn, pharmacogenetic testing makes it possible to predict the pharmacological response to the drug and is one of the promising prognostic tests that allow to assess the characteristics of individual sensitivity to the appointment of drug therapy. Particular emphasis in this review of the literature is made on a comprehensive approach, including the use ofpharmacogenetic and functional studies, the results and prospects of the results and prospects ofpharmacogenetic testing in the personalization of antiplatelet therapy of ischemic stroke in order to achieve the effectiveness of the greatest effect of antiplatelet drugs and reduce the risk of adverse reactions. This approach is important because it allows you to correct antiplatelet therapy in the treatment and secondary prevention of ischemic stroke in a timely manner, which makes it possible to develop an algorithm to achieve the effectiveness of antiplatelet therapy, choose an individual dose of the drug and the treatment regimen.

Publisher

Medical Informational Agency Publishers

Subject

General Medicine

Reference65 articles.

1. Vorob’eva N.M. Antithrombotic therapy in patients who underwent ischemic stroke: the place of acetylsalicylic acid and clopidogrel. Russkii Meditsinskiil zhurnal. 2015; (5): 268. (in Russian)

2. Gusev E.I., Konovalov A.N., Skvortsova V.I. Neurology and neurosurgery: a textbook: in 2 vols. Vol. 2. Moscow: GEOTAR-Media, 2009. (in Russian)

3. Martynchik S.A., Sokolova O.V. Medico-economic assessment and rationale for improving the organizational forms of providing inpatient care for cerebral stroke [Electronic resource]. Social’nye aspekty zdorov’ya naseleniya: ehlektronnyj nauchnyj zhurnal. 2013; 2 (30). (in Russian)

4. Skvortsova V.I. Reducing morbidity, mortality and disability from strokes in the Russian Federation. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. Insul’t: prilozhenie k zhurnalu 2007; specvypusk: 25-27. (in Russian)

5. Starodubtsev O.S., Begicheva S.V. Analysis of the incidence of stroke using information technology. Fundamental’nye issledovaniya. 2012; 8 (2): 424–7. (in Russian)